ArticleJournal of clinical hypertension (Greenwich, Conn.)2026
Trends in Central Obesity Prevalence Among Adults With Hypertension in the United States, 2001-2023.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Central obesity drives hypertension progression, but long-term trend data in hypertensive populations are lacking. This study using National Health and Nutrition Examination Survey (NHANES) data (2001-2023), 28,666 adult hypertensive participants were included. Central obesity was defined as waist circumference ≥102 cm (men) or ≥88 cm (women). Central obesity was further categorized into three severity grades: Grade I (men 102-110 cm, women 88-95 cm), Grade II (men 110-120 cm, women 95-105 cm), and Grade III (men ≥120 cm, women ≥105 cm). Age-standardized prevalence trends were analyzed with Joinpoint software. Overall central obesity prevalence increased significantly from 59.2% (2001-2004) to 69.7% (2021-2023, p < 0.001). Females (72.2%-80.5%) had higher rates than males (49.2%-61.3%). Severe (Grade III) obesity rose most prominently (20.1%-30.9%, p < 0.001). The 20-44 age group showed the largest absolute increase (50.5%-66.1%) and contributed 46.5% to the overall rise. In conclusion, central obesity, particularly severe forms, increased steadily among US hypertensive adults. Younger adults contributed most, highlighting the need for targeted interventions to reduce cardiovascular burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.